This section contains the latest highlighted research for patients from ASCO medical journals, including the Journal of Clinical Oncology, as well as an archive of research highlights from previous ASCO scientific meetings (2011-2015). For the latest research highlights from more recent ASCO meetings, visit the Cancer.Net Blog or check out Cancer.Net’s audio podcasts and videos for patients.
To search this archive, use the drop-down menu below. You can select a specific year, meeting or publication, and/or a specific topic, such as a type of cancer. Selecting "All" will take you to a complete list of articles that appear under all categories.
As part of an ongoing study, researchers found that a new immune-based treatment controlled the growth of multiple myeloma for longer than standard treatment. This new treatment, elotuzumab, works in two different ways to treat myeloma. It is able to directly target multiple myeloma cells and boost a part of the immune system that helps control the growth of cancer cells.
A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.
Two phase III Children’s Oncology Group studies found that using additional drugs with standard therapy lowered the chance that Wilms tumor with a specific genetic change returned after treatment. Wilms tumor is a rare type of cancer that begins in a child’s kidney. When it comes back after treatment, it is called a relapse or recurrence.
A recent study showed that people who took a form of vitamin B3 called nicotinamide developed fewer non-melanoma skin cancers. Nicotinamide is a low-cost vitamin supplement available over the counter. Previous research has suggested that nicotinamide helps protect skin cells from the sun and repair sun damage.
A new study that analyzed data from more than 87,500 men with prostate cancer shows that the number diagnosed with higher-risk disease increased between 2011 and 2013. According to these results, the number of men diagnosed with either intermediate- or high-risk disease has increased by nearly 6% since 2011. These findings are interesting because in 2011 the U.S. Preventive Services Task Force (USPSTF) recommended that PSA testing not be used for prostate cancer screening, regardless of a man’s age.
A recent study suggests that people with locally advanced kidney cancer should not take either sorafenib (Nexavar) or sunitinib (Sutent) after surgery.
For many types of cancer, doctors are able to run laboratory tests to identify specific genes, proteins, and other factors unique to the tumor that help determine the best treatment option for each patient. However, there are currently no tests to help doctors select the best treatment option for men with metastatic castration-resistant prostate cancer (mCRPC).
After analyzing data from nearly 180,000 men collected in the Surveillance, Epidemiology, and End Results (SEER) database, researchers have found that the risk of developing prostate cancer is higher in men who have already had testicular cancer than those who have not.
A new study that analyzed data from 945 men with prostate cancer raises questions about recommending active surveillance to men with intermediate-risk disease.
A recent review of information from 145 patients with rectal cancer suggests that those who had no signs of cancer after receiving a combination of chemotherapy and radiation therapy could safely avoid or postpone surgery.